Cardiology

Once one of the country healthcare system's greatest successes, CVD and related mortality is rising again. What's its true cause?

The community-based program intent on improving black men's blood pressure care will revamp its practice headed into 2019.

This past year came with a multitude of new FDA approvals for antiretroviral therapies as well as research highlighting HIV and various comorbidities.

African-American patients with moderate or severe sleep apnea have twice, or 3.5 times, the risk of resistant hypertension, respectively.

Providers should be aware that periodontal disease may hinder the efficacy of blood pressure medication.

The seemingly complicated maneuvers of getting patient’s cholesterol better can be resolved with common sense. What’s best for the patient?

Since the PCSK9 inhibitors were approved for cholesterol management by the FDA in 2015, they have been frequently compared.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

A new study found the annual top-50 ranking is a reliable indicator of cardiovascular disease mortality and patient satisfaction.

Topline data shows that the diabetes medication is non-inferior to placebo with regard to a composite outcome of major adverse cardiovascular events.

Prevalence of hypertension in HIV-positive persons is not attributed to antiretroviral drug treatment in largest adverse event surveillance study.

The septic shock therapy was approved by the FDA last December. How has it fared in its first year of real-world clinical use?

How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.

Jay Edelberg, MD, PhD, of Sanofi and Robert Sanchez, PhD, of Regeneron shared about the recent ODYSSEY OUTCOMES trial of alirocumab (Praluent) and accompanying cost-effectiveness study.

“Reassuring” results from a study of 11,692 individuals show that statin use does not affect the effectiveness of the influenza vaccine.

The FDA has expanded Novartis’ eltrombopag (Promacta) to include first-line treatment for adults and pediatric patients aged 2 years and older with severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST).

In analysis, the therapy plus standard immunosuppressive therapy resulted in a complete response rate 27% greater than that historically observed in patients treated with lone IST, over 6 months.

About 21% to 74% of patients with AF will also have obstructive sleep apnea. What is one medical center doing to find these patients in their cardiology department?

Investigators have found that lowering LDL cholesterol may not be the only way to reduce cardiovascular events—reducing inflammation may be the key to improving outcomes.

A popularizing procedure among stroke centers was the basis of clinical research for the medical center, and is now improving in practice.

Using relevant clinical trial data, investigators created a price tag of about $6300 annually for the very effective, often costly inhibitor.

James Januzzi, MD, discusses trial results from the PIONEER-HF trial and what cardiologists and hospitalists should know about sacubitril-valsartan.

How surgeons' duties surround the entire invasive process, and therefore make them something closer to specialists.

Strengths of the DECLARE-TIMI 58 trial included a large primary prevention population, while the nature of the study meant that adherence was likely higher than it would be in a standard setting.

Steven Nissen, MD, discusses the updates to the cholesterol guidelines and how the risk calculator should not be considered an end-all be-all.